Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting
Monopar Therapeutics (Nasdaq: MNPR) is presenting data on its lead radiopharma program MNPR-101-Zr at the 2024 SNMMI Annual Meeting. The data demonstrates the potential of urokinase plasminogen activator receptor (uPAR) as a target for radiopharma cancer treatment. In preclinical trials on mice with human tumor xenografts, MNPR-101-Zr showed strong and durable tumor uptake in triple-negative breast, colorectal, and pancreatic cancers, with minimal accumulation in bone and healthy tissues. Monopar has started a Phase 1 clinical trial for MNPR-101-Zr in advanced cancer patients, led by Prof. Rodney Hicks. The trial details are available under study identifier NCT06337084.
- Monopar's MNPR-101-Zr demonstrated strong and durable tumor uptake in preclinical trials.
- The data highlights MNPR-101-Zr's effectiveness in targeting uPAR in triple-negative breast, colorectal, and pancreatic cancers.
- The optimization of MNPR-101-Zr resulted in higher tumor uptake and drug stability.
- The Phase 1 clinical trial for MNPR-101-Zr has been initiated, marking a significant step forward.
- The study is led by Prof. Rodney Hicks, an internationally recognized radiopharmaceutical physician.
- The presented data is still in the preclinical stage and has yet to be validated in human trials.
- There is inherent risk in transitioning from preclinical to clinical stages, with potential for unforeseen issues.
- Further clinical trials are required before MNPR-101-Zr can be considered for broader use, which could delay market entry.
- Initial clinical trial results are not yet available, making it difficult to assess real-world efficacy.
WILMETTE, Ill., June 10, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, is presenting today data from the preclinical development of its novel first-in-class lead radiopharma program MNPR-101-Zr at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Toronto, Canada. SNMMI is the premier educational, scientific, and research event in the radiopharma space. Monopar’s poster presentation can be found at the following link: https://www.monopartx.com/pipeline/mnpr-101/snmmi-poster-june-2024.
Monopar’s poster highlights the potential promise of both the urokinase plasminogen activator receptor (uPAR) as a radiopharma cancer target for solid tumors as well as MNPR-101 as a targeting agent against uPAR. The data presented demonstrate robust, durable tumor uptake of Zr-89 radiolabeled MNPR-101 (MNPR-101-Zr) in human tumor xenograft mouse models of triple-negative breast, colorectal, and pancreatic cancers. Monopar’s optimization of the MNPR-101-Zr construct achieved markedly higher tumor uptake and drug stability while minimizing accumulation in bone and healthy tissue.
Monopar recently initiated a first-in-human Phase 1 imaging and dosimetry clinical trial in advanced cancer patients with MNPR-101-Zr. The study is led by internationally recognized radiopharmaceutical physician Prof. Rodney Hicks, founder of the Melbourne Theranostic Innovation Centre (MTIC). Further information about the MNPR-101-Zr trial is available at www.ClinicalTrials.gov under study identifier NCT06337084.
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, including Phase 1-stage MNPR-101-Zr for imaging advanced cancers and late preclinical-stage MNPR-101 radio-immuno-therapeutic (RIT) for the treatment of advanced cancers. For more information, visit: www.monopartx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of these forward-looking statements include statements concerning: promise of both the urokinase plasminogen activator receptor (uPAR) as a radiopharma cancer target for solid tumors as well as MNPR-101 as a targeting agent against uPAR, any implied translation of data from preclinical human tumor xenograft models to human clinical data may not be realized including optimization of the MNPR-101-Zr construct in preclinical models. The forward-looking statements involve risks and uncertainties including, but not limited to: that future preclinical or clinical data will not be as promising as the data to date; not enrolling the Phase 1 clinical trial; that MNPR-101-Zr may cause unexpected serious adverse effects or fail to image; the potential for the Australian regulatory authority (HREC) to put the Phase 1 trial on clinical hold at any time; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
CONTACT:
Monopar Therapeutics Inc.
Investor Relations
Kim R. Tsuchimoto
Chief Financial Officer
kimtsu@monopartx.com
Follow Monopar on social media for updates:
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics
FAQ
What is Monopar Therapeutics presenting at the 2024 SNMMI Annual Meeting?
What types of cancers did MNPR-101-Zr show effectiveness against in preclinical trials?
What is the significance of the Phase 1 clinical trial for MNPR-101-Zr?
Who is leading the Phase 1 clinical trial for MNPR-101-Zr?
Where can more information about the MNPR-101-Zr trial be found?
